Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
Related Questions
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?
How do you decide on long term immunosuppression therapy for Susac Syndrome?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
How do you mitigate the risk of rebound disease activity when discontinuing S1p inhibitors or Tysabri in patients with multiple sclerosis?
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
How would you manage a patient with LGI-1 encephalitis with faciobracial dystonic seizures who has not improved with 3 days of intravenous steroids?
What are your vaccine recommendations while patients are on biologics?
